Drugs / Atoderm SOS
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT04986384 Comparator | Jan 2019 → Apr 2021 | atopic eczema | Prof. HON Kam Lun Ellis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atoderm 'SOS' | “Recently, a new spray named Atoderm 'SOS' is developed.” NCT04986384 ↗ |
| Action | Inhibit | “claimed to inhibit the release TSLP and NGF” NCT04986384 ↗ |
| Route | Topical | “using the Atoderm 'SOS' spray topically whenever necessary” NCT04986384 ↗ |
| Target | NGF | “claimed to inhibit the release TSLP and NGF” NCT04986384 ↗ |
| Target | TSLP | “claimed to inhibit the release TSLP and NGF” NCT04986384 ↗ |